However, TNFis pose significant risks in patients with pre-existing HF, and the 2021 ACR guidelines recommend switching to non-TNF biologics or targeted synthetic DMARDs in patients with RA and HF (NYHA classes II-IV or EF < 50%). This evidence concerns the gene TNF and rheumatoid arthritis.